There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a ...

Shares of pharmaceutical company Merck (NYSE: MRK) were recently down about 40% over the past year, partly due to concerns ...

However, beneath this success lies a growing concern: the sustainability of this growth trajectory, particularly as ...

Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider from ...

The Dow Jones Industrial Average (DJINDICES: ^DJI) index edged 3.9% higher in May, with 70% of its 30 constituent stocks ...

Citizens Financial Group (CFG) will be expanding its share buyback program to $1.5 billion. Pharmaceutical giant Merck (MRK) ...

Merck's Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE ...

Merck & Co. Inc. closed 39.23% short of its 52-week high of $134.63, which the company reached on June 25th.

The stock's fall snapped a three-day winning streak.

Merck's oral PCSK9 inhibitor enlicitide showed significant LDL-C reductions in two Phase 3 trials, with no major safety ...